サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1646787

単球活性化試験（MAT）の世界市場

Monocyte Activation Tests (MAT)

出版日
ページ情報
英文 244 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
単球活性化試験（MAT）の世界市場
出版日: 2025年01月31日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 244 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

単球活性化試験（MAT）の世界市場は2030年までに2億8,550万米ドルに達する見込み

2024年に9,470万米ドルと推定される単球活性化試験（MAT）の世界市場は、分析期間2024-2030年にCAGR 20.2%で成長し、2030年には2億8,550万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるMATキットは、CAGR18.5%を記録し、分析期間終了時には1億5,720万米ドルに達すると予測されます。MAT試薬セグメントの成長率は、分析期間でCAGR 22.5%と推定されます。

米国市場は2,520万米ドルと推定、中国はCAGR19.0％で成長予測

米国の単球活性化試験（MAT）市場は、2024年には2,520万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 19.0％で推移し、2030年には4,340万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ18.3％と17.5％と予測されています。欧州では、ドイツがCAGR 15.0%で成長すると予測されています。

世界の単球活性化試験市場- 主要動向と促進要因のまとめ

単球活性化試験（MAT）とは何か、なぜ現代のバイオ医薬品の安全性において重要なのか？

単球活性化試験（MAT）は、医薬品、医療機器、生物学的製剤に含まれる発熱誘発物質（パイロジェン）の存在を検出するインビトロアッセイです。これらの検査はヒト単球または単球細胞株を利用し、パイロジェンに暴露されるとIL-6やTNF-αのような炎症性サイトカインを放出します。MATは、従来のウサギパイロジェンテスト（RPT）やリムルスアメーボサイトライセート（LAL）テストに代わる信頼性の高い検査法であり、注射薬、ワクチン、点滴液、埋め込み型医療機器の安全性と品質を確保する上で重要なツールとなっています。

単球活性化検査の重要性は、その正確さ、ヒトとの関連性、そしてエンドトキシンと非エンドトキシンパイロジェンの両方を検出する能力にあります。エンドトキシンのみを検出するLAL検査とは異なり、MATはより広範なパイロジェンを同定できるため、医薬品や医療機器の包括的な安全性評価が保証されます。MATは、検査における動物の使用を最小限に抑えることを目的とした3R（Replacement、Reduction、Refinement）の原則に沿ったものです。これにより、MATはパイロジェン検出において効果的であるだけでなく、安全性試験における最新の規制要件や業界標準に倫理的に沿ったものとなっています。

技術の進歩は単球活性化検査市場をどのように形成しているか？

技術の進歩は、単球活性化試験の効率、感度、再現性を著しく向上させ、医薬品安全性試験の革新を促進しています。主要な開発のひとつは、MATの一貫性と入手可能性を向上させた凍結保存ヒト単球の使用です。凍結保存された細胞は、標準化され、すぐに使用できる検査ソリューションを提供し、検査結果のばらつきを抑え、異なる検査室間での再現性を向上させます。この進歩により、特に新鮮血液の供給が限られている、あるいは現実的でない環境において、MATがより利用しやすくなった。

自動化されたMATプラットフォームの開発により、パイロジェン検査の拡張性と効率性がさらに向上しました。自動化システムは、サンプル調製からデータ解析までの検査プロセス全体を合理化し、手作業によるミスを減らし、スループットを向上させます。自動化によってMATは、製品の安全性を確保するために大量の検査が必要とされるバイオ医薬品製造における大規模スクリーニングにより適したものとなった。さらに、ハイスループットスクリーニング（HTS）技術の使用により、発熱物質の同定が迅速に行えるようになり、医薬品開発やバッチリリース時の迅速な安全性評価をサポートしています。

マルチプレックス・サイトカイン・アッセイやリアルタイムPCRなどの分析技術の進歩により、MATの感度と精度が向上しています。これらの技術により、複数のサイトカインの同時測定が可能となり、より包括的なパイロジェン活性のプロファイルが得られます。高度なデータ解析や人工知能（AI）ツールとの統合により、MAT結果の解釈がさらに改善され、製品安全性評価においてより迅速かつ正確な意思決定が可能になった。これらの技術革新は、単球活性化試験の能力を拡大するだけでなく、医薬品安全性試験における自動化、高感度化、倫理的試験を目指す幅広い動向にも合致しています。

さまざまな分野での単球活性化試験の新たな応用とは？

単球活性化試験は、バイオ医薬品、医療機器、ワクチンにおける信頼性が高く、倫理的で包括的なパイロジェン検出の必要性により、様々なセクターで用途が拡大しています。バイオ医薬品分野では、MATはモノクローナル抗体、組換えタンパク質、細胞・遺伝子治療などの生物製剤を含む注射薬の検査に広く使用されています。エンドトキシンと非エンドトキシンパイロジェンの両方を検出するMATの能力は、従来のLAL検査では特定の汚染物質を見逃す可能性がある、これらの複雑な生物学的製剤の安全性を確保するために不可欠です。

ワクチン産業では、MATはワクチン、特にmRNAやウイルスベクターのような最新の方法で開発されたワクチンの安全性を確保する上で重要な役割を果たしています。迅速な開発と大量生産の必要性を考えると、MATはワクチンの品質管理パイプラインに組み込むことができる、信頼性の高い非動物ベースの代替手段を提供します。MATは、迅速かつ倫理的で正確な検査が不可欠であったCOVID-19パンデミックの際に開発されたワクチンのような、新しいワクチン製剤中のパイロジェン検出において特に有用です。

医療機器産業では、MATは移植可能な機器、透析液、点滴液の発熱性汚染物質の検査に使用されています。医療機器は体液と直接接触することが多いため、厳格なパイロジェン検査は有害な免疫反応を防ぐために必要です。MATは、これらの医療機器のより包括的な安全性評価を提供し、規制遵守と患者の安全性向上をサポートします。化粧品分野では、MATは皮膚充填剤のような注射可能な化粧品の安全性を評価するために使用され、有害なパイロジェンが含まれていないことを保証します。

研究開発分野では、医薬品や製品開発の初期段階でMATを使用するケースが増えています。前臨床試験でMATを使用することで、研究者は開発プロセスの初期段階で発熱性リスクを特定・除去し、規制当局の承認の可能性を高め、後期の失敗によるコストを削減することができます。これらの分野でのMATの応用拡大により、安全性の向上、倫理的試験のサポート、医薬品・医療機器・関連製品の品質管理の効率化においてMATが果たす重要な役割が浮き彫りになっています。

単球活性化検査市場の成長を促すものは何か？

単球活性化試験（MAT）市場の成長は、包括的なパイロジェン検査に対する需要の増加、倫理的検査法の採用の増加、バイオ医薬品開発の進歩など、いくつかの要因によってもたらされます。主な成長要因の一つは、非動物試験法へのシフトです。FDAやEMAのような規制機関が3R原則に沿ったin-vitro法の採用を推進する中、MATはウサギパイロジェンテスト（RPT）のような動物ベースのパイロジェンテストの効果的な代替法として支持を集めています。このような倫理的検査に対する規制の後押しにより、医薬品・医療機器製造におけるMATの採用が加速しています。

バイオ医薬品や先端治療の複雑化がMATの需要をさらに促進しています。生物製剤、バイオシミラー、細胞・遺伝子治療、mRNAワクチンの台頭により、さまざまなパイロジェンを検出できる安全性検査の必要性が高まっています。エンドトキシンと非エンドトキシンの両方のパイロジェンを同定できるMATの能力は、従来のエンドトキシン検査では不十分な場合がある、これらの先進的治療にとって好ましい選択となります。

自動化、ハイスループットスクリーニング、凍結保存細胞技術の進歩もMAT市場の成長に寄与しています。自動化とハイスループット機能により、MATはよりスケーラブルで効率的なものとなり、大規模なバイオ医薬品生産とバッチリリース試験での利用を支えています。凍結保存された単球が利用できるようになったことで、MATの信頼性が向上し、ばらつきが少なくなり、さまざまな検査施設で日常的に使用できるようになりました。

製薬・医療機器業界における厳しい安全規制と品質管理基準が、MATの採用をさらに後押ししています。包括的なパイロジェン試験に対する規制要件により、メーカーは堅牢な安全性試験プロトコルを実施することが不可欠となっています。MATはこれらの規制要件を満たすだけでなく、より迅速で信頼性が高く、倫理的な方法でパイロジェン検出を行うことができるため、最新の安全性評価戦略の重要な要素となっています。

セルベースアッセイにおける技術革新の進行、in-vitro検査に対する規制当局の支援、バイオ医薬品の複雑化により、MAT市場は力強い成長を遂げようとしています。こうした動向と、信頼性が高く包括的で倫理的なパイロジェン検出に対する需要の高まりが相まって、MATは医薬品の品質管理、バイオ医薬品開発、さまざまな分野における規制遵守に不可欠な要素となっています。

セグメント

製品タイプ（MATキット、MAT試薬）、供給源（末梢血単核細胞（PBMC）ベース、細胞株ベース）、最終用途（医薬品最終用途、バイオテクノロジー最終用途、医療機器最終用途、その他最終用途）

調査対象企業の例（全41件）

  • Becton, Dickinson & Company
  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Microcoat Biotechnologie GmbH
  • Sanquin
  • Solvias AG
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP16601

Global Monocyte Activation Tests (MAT) Market to Reach US$285.5 Million by 2030

The global market for Monocyte Activation Tests (MAT) estimated at US$94.7 Million in the year 2024, is expected to reach US$285.5 Million by 2030, growing at a CAGR of 20.2% over the analysis period 2024-2030. MAT Kits, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$157.2 Million by the end of the analysis period. Growth in the MAT Reagents segment is estimated at 22.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.2 Million While China is Forecast to Grow at 19.0% CAGR

The Monocyte Activation Tests (MAT) market in the U.S. is estimated at US$25.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$43.4 Million by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.3% and 17.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global Monocyte Activation Tests Market - Key Trends & Drivers Summarized

What Are Monocyte Activation Tests (MAT), and Why Are They So Crucial in Modern Biopharmaceutical Safety?

Monocyte Activation Tests (MAT) are in-vitro assays that detect the presence of pyrogens—fever-inducing substances, in pharmaceutical products, medical devices, and biologicals. These tests utilize human monocytes or monocytic cell lines, which, upon exposure to pyrogens, release pro-inflammatory cytokines like IL-6 and TNF-α. MAT offers a reliable alternative to traditional rabbit pyrogen tests (RPT) and Limulus Amebocyte Lysate (LAL) tests, making it a critical tool in ensuring the safety and quality of injectable drugs, vaccines, intravenous solutions, and implantable medical devices.

The importance of monocyte activation tests lies in their accuracy, human relevance, and ability to detect both endotoxins and non-endotoxin pyrogens. Unlike LAL tests, which only detect endotoxins, MAT can identify a broader spectrum of pyrogens, ensuring comprehensive safety assessments for pharmaceuticals and medical devices. MAT is aligned with the principles of the 3Rs (Replacement, Reduction, Refinement), which aim to minimize the use of animals in testing. This makes MAT not only effective in detecting pyrogens but also ethically aligned with modern regulatory requirements and industry standards in safety testing.

How Are Technological Advancements Shaping the Monocyte Activation Tests Market?

Technological advancements have significantly enhanced the efficiency, sensitivity, and reproducibility of Monocyte Activation Tests, driving innovation in pharmaceutical safety testing. One of the major developments is the use of cryopreserved human monocytes, which have improved the consistency and availability of MAT. Cryopreserved cells provide standardized and ready-to-use testing solutions, reducing variability in test results and improving reproducibility across different laboratories. This advancement has made MAT more accessible, especially in settings where fresh blood supply is limited or impractical.

The development of automated MAT platforms has further improved the scalability and efficiency of pyrogen testing. Automated systems streamline the entire testing process, from sample preparation to data analysis, reducing manual errors and enhancing throughput. Automation has made MAT more suitable for large-scale screening in biopharmaceutical manufacturing, where high-volume testing is required to ensure product safety. Additionally, the use of high-throughput screening (HTS) technologies has enabled faster identification of pyrogens, supporting rapid safety assessments during drug development and batch release.

Advancements in analytical techniques, such as multiplex cytokine assays and real-time PCR, have increased the sensitivity and accuracy of MAT. These techniques allow for the simultaneous measurement of multiple cytokines, providing a more comprehensive profile of pyrogenic activity. Integration with advanced data analytics and artificial intelligence (AI) tools has further improved the interpretation of MAT results, enabling faster and more precise decision-making in product safety evaluations. These technological innovations not only expand the capabilities of monocyte activation tests but also align with broader trends toward automation, higher sensitivity, and ethical testing in pharmaceutical safety.

What Are the Emerging Applications of Monocyte Activation Tests Across Different Sectors?

Monocyte Activation Tests are finding expanding applications across various sectors, driven by the need for reliable, ethical, and comprehensive pyrogen detection in biopharmaceuticals, medical devices, and vaccines. In the biopharmaceutical sector, MAT is widely used for testing injectable drugs, including biologics like monoclonal antibodies, recombinant proteins, and cell or gene therapies. The ability of MAT to detect both endotoxin and non-endotoxin pyrogens is critical for ensuring the safety of these complex biological products, where traditional LAL tests may miss certain contaminants.

In the vaccine industry, MAT plays a vital role in ensuring the safety of vaccines, particularly those developed through modern methods like mRNA or viral vectors. Given the need for rapid development and mass production, MAT offers a reliable, non-animal-based alternative that can be integrated into vaccine quality control pipelines. It is particularly valuable in detecting pyrogens in new vaccine formulations, such as those developed during the COVID-19 pandemic, where rapid, ethical, and accurate testing was essential.

In the medical device industry, MAT is used to test implantable devices, dialysis fluids, and intravenous solutions for pyrogenic contaminants. Since medical devices often come into direct contact with body fluids, rigorous pyrogen testing is necessary to prevent adverse immune reactions. MAT provides a more comprehensive safety assessment for these devices, supporting regulatory compliance and improving patient safety. In the cosmetic sector, MAT is used to evaluate the safety of injectable cosmetic products like dermal fillers, ensuring they are free from harmful pyrogens.

In research and development, MAT is increasingly employed during the early stages of drug and product development. Its use in preclinical testing allows researchers to identify and eliminate pyrogenic risks early in the development process, improving the likelihood of regulatory approval and reducing costs associated with late-stage failures. The expanding applications of MAT across these sectors highlight its critical role in enhancing safety, supporting ethical testing, and improving efficiency in the quality control of pharmaceuticals, medical devices, and related products.

What Drives Growth in the Monocyte Activation Tests Market?

The growth in the Monocyte Activation Tests (MAT) market is driven by several factors, including increasing demand for comprehensive pyrogen testing, rising adoption of ethical testing methods, and advancements in biopharmaceutical development. One of the primary growth drivers is the shift toward non-animal testing methods. As regulatory agencies like the FDA and EMA promote the adoption of in-vitro methods aligned with the 3Rs principles, MAT has gained traction as an effective alternative to animal-based pyrogen tests like the rabbit pyrogen test (RPT). This regulatory push toward ethical testing has accelerated the adoption of MAT in pharmaceutical and medical device manufacturing.

The growing complexity of biopharmaceuticals and advanced therapies has further fueled demand for MAT. With the rise of biologics, biosimilars, cell and gene therapies, and mRNA vaccines, there is a greater need for safety tests that can detect a wide range of pyrogens. MAT’s ability to identify both endotoxin and non-endotoxin pyrogens makes it a preferred choice for these advanced therapies, where traditional endotoxin tests may be insufficient.

Advancements in automation, high-throughput screening, and cryopreserved cell technology have also contributed to the growth of the MAT market. Automation and high-throughput capabilities have made MAT more scalable and efficient, supporting its use in large-scale biopharmaceutical production and batch release testing. The availability of cryopreserved monocytes has improved MAT’s reliability, reducing variability and making it more practical for routine use across different testing sites.

Stringent safety regulations and quality control standards in the pharmaceutical and medical device industries have further driven the adoption of MAT. Regulatory requirements for comprehensive pyrogen testing have made it essential for manufacturers to implement robust safety testing protocols. MAT not only meets these regulatory requirements but also offers a faster, more reliable, and ethical approach to pyrogen detection, making it a key component of modern safety assessment strategies.

With ongoing innovations in cell-based assays, regulatory support for in-vitro testing, and the growing complexity of biopharmaceutical products, the MAT market is poised for robust growth. These trends, combined with increasing demand for reliable, comprehensive, and ethical pyrogen detection, make MAT a vital component of pharmaceutical quality control, biopharmaceutical development, and regulatory compliance across various sectors.

SCOPE OF STUDY:

The report analyzes the Monocyte Activation Tests (MAT) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (MAT Kits, MAT Reagents); Source (Peripheral Blood Mononuclear Cell (PBMC) Based, Cell Line Based); End-Use (Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Becton, Dickinson & Company
  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Microcoat Biotechnologie GmbH
  • Sanquin
  • Solvias AG
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Monocyte Activation Tests - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Need for Pyrogen Testing Drives Demand for Monocyte Activation Tests
    • Increasing Focus on Patient Safety in Drug Development Sets the Stage for Market Growth
    • Strong Regulatory Support for Safer Drug Testing Strengthens Business Case
    • Growing Use in Biopharmaceutical Production Expands Addressable Market
    • Growing Role in Quality Control Generates Demand in Pharmaceutical Industry
    • Increasing Focus on Animal-free Testing Drives Adoption of Monocyte Activation Tests
    • Expanding Use in Vaccine Safety Testing Sets the Stage for Market Expansion
    • Rising Focus on Endotoxin-free Manufacturing Generates Demand
    • Use in Cell Therapy Development Propels Monocyte Activation Test Market
    • Increasing Applications in Oncology and Immunotherapy Strengthen Market Position
    • Growing Role in Risk Assessment for Blood Products Drives Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Monocyte Activation Tests (MAT) Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Monocyte Activation Tests (MAT) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for MAT Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for MAT Kits by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for MAT Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for MAT Reagents by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Peripheral Blood Mononuclear Cell (PBMC) Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Peripheral Blood Mononuclear Cell (PBMC) Based by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cell Line Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Cell Line Based by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharmaceutical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharmaceutical End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biotechnology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Biotechnology End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Medical Device End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Medical Device End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION